Becton, Dickinson and Company

Stand by, your program is about to begin. Should you need audio assistance during today's program, please press star zero. Hello and welcome to BD's earning call for the second quarter of fiscal 2022.

At the request of BD, today's call is being recorded and will be available for replay through May 12, 2022 on BD's investor relation website, at bd.com or by phone at 866-342-8591 for domestic calls and the area code plus 1-203-518-9713 for international calls. The replay bridges are now dedicated so you no longer need a conference ID to hear the replay. For today's call, all parties have been placed in a listen-only mode until the question and answer session. I will now turn the call over to BD.

Good morning, and welcome to BD's earnings call. I'm Francesca DiMartino, Senior Vice President and Head of Investor Relations. On behalf of the BD team, thank you for joining us. This call is being made available via audio webcast at BD.com. Earlier this morning, BD released its results for the second quarter of fiscal 2022. We also posted an earnings presentation that provides additional details on our performance. The press release and presentation can be accessed on the IR website at investors.bd.com. Leading today's call are Tom Follin, BD's Chairman, Chief Executive Officer, and President, and Chris Del Orifice, Executive Vice President and Chief Financial Officer. Tom will provide highlights of our performance in the continued execution of our BD 2025 strategy, Chris will then provide a financial review and our updated outlook for fiscal 2022. The Q2 results we will be discussing today include the results of our former diabetes care business as the spin of Empecta was completed on April 1st, subsequent to quarter end. On April 14th, an 8K was filed to provide recasted historical financial information reflecting the results of operations of our former diabetes care business is discontinued operations for the 2019, 2020, and 2021 fiscal years and the first quarter of fiscal 2022. On today's call, we will give an updated outlook for fiscal 22 for both Legacy BD, which includes our former diabetes care business, and BD Remain Co. We anticipate recasted financial information for the second quarter of FY22 will be available by the end of May. In the meantime, to assist you with FY22 Remain Co-Models, we are providing estimated impacts of excluding our former diabetes care business from our Q2 results. We don't expect the Q2 recasted financial information to differ materially from the estimated impacts nor affect the updated outlook for FY22 that we are providing today. We also do not plan to comment on diabetes care after this quarter. In addition to our prepared remarks, you can find this information on our earnings presentation that is posted on our IR website. Following the prepared remarks, Tom and Chris will be joined for Q&A by our segment presidents. Alberto Mas, president of the medical segment, Simon Campion, president of the interventional segment, and Dave Hickey, president of the life sciences segment. Before we get started, I want to remind you that we will be making forward-looking statements today. I encourage you to read the disclaimer in our earnings presentation slides and the disclosures in our SEC filings, which are both available on the Investor Relations website. Unless otherwise specified, all comparisons will be on a year-over-year basis versus the relevant period. Revenue percentage changes are on an FX neutral basis unless otherwise noted. When we refer to any given period, we are referring to the fiscal period unless we specifically noted as a calendar period. I would also call your attention to the basis of presentation slide, which defines terms you will hear today, such as base revenues and base margins, which refer to a result excluding estimated COVID-only testing. With that, I am very pleased to turn it over to Tom.